ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
128.89
+1.19 (+0.93%)
As of 12:18PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close127.70
Open127.32
Bid128.44 x 1000
Ask128.56 x 800
Day's Range125.83 - 128.89
52 Week Range102.10 - 144.67
Volume309,741
Avg. Volume1,499,758
Market Cap28.724B
Beta (3Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.45
Earnings DateOct 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est163.41
Trade prices are not sourced from all markets
  • Alexion Pharmaceuticals (ALXN) Q3 Earnings Preview: What to Know Ahead of the Release
    Zacks2 hours ago

    Alexion Pharmaceuticals (ALXN) Q3 Earnings Preview: What to Know Ahead of the Release

    Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Gauging Analysts’ Views of Sarepta Stock in October
    Market Realistyesterday

    Gauging Analysts’ Views of Sarepta Stock in October

    Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.

  • A Look at Sarepta Therapeutics’ Stock Performance
    Market Realist2 days ago

    A Look at Sarepta Therapeutics’ Stock Performance

    Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

  • Key Collaborations Bode Well for Sarepta Therapeutics
    Market Realist2 days ago

    Key Collaborations Bode Well for Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.

  • Analyzing Sarepta’s Product Pipeline
    Market Realist2 days ago

    Analyzing Sarepta’s Product Pipeline

    Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene. 

  • Understanding Sarepta Therapeutics’ Operational Performance
    Market Realist5 days ago

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.

  • GlobeNewswire6 days ago

    Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • How Analysts View Alexion Pharmaceuticals Stock in October
    Market Realist6 days ago

    How Analysts View Alexion Pharmaceuticals Stock in October

    In October, 18 analysts are covering Alexion Pharmaceuticals (ALXN) stock. Five of them have recommended a “strong buy,” 11 have recommended a “buy,” and two have recommended a “hold.”

  • Alexion Pharmaceuticals’ Operational Performance
    Market Realist7 days ago

    Alexion Pharmaceuticals’ Operational Performance

    Alexion Pharmaceuticals’ (ALXN) total operating expenses increased from $602.4 million in the second quarter of 2017 to $1.35 billion in the second quarter of 2018. It generated operating income of $226.7 million in the second quarter of 2017. In the second quarter of 2018, it had an operating loss of $400.1 million.

  • How Alexion Pharmaceuticals Is Positioned in October
    Market Realist7 days ago

    How Alexion Pharmaceuticals Is Positioned in October

    Alexion Pharmaceuticals (ALXN) is a leader in complement inhibition. It focuses on hematology, nephrology, neurology, and metabolic disorders. In this series, we’ll explore its financials, valuation metrics, latest developments, and analyst recommendations. 

  • Analyzing Alexion Pharmaceuticals’ Top-Line Trends
    Market Realist7 days ago

    Analyzing Alexion Pharmaceuticals’ Top-Line Trends

    Alexion Pharmaceuticals’ (ALXN) revenues increased $132.3 million to $1.04 billion in the second quarter of 2018 compared to the second quarter of 2017. For fiscal 2018 and fiscal 2019, Alexion Pharmaceuticals is expected to generate revenues of $4.04 billion and $4.72 billion, respectively, compared to $3.55 billion in fiscal 2017. Fiscal 2018 gross margins for its peers Abbott Laboratories (ABT), Amgen (AMGN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 59.10%, 85.94%, 70.09%, 69.64%, and 79.21%, respectively.

  • Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again
    Zacks7 days ago

    Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again

    Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • A Look at Portola Pharmaceuticals’ Financial Performance
    Market Realist9 days ago

    A Look at Portola Pharmaceuticals’ Financial Performance

    Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Business Wire13 days ago

    Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018

    Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.

  • Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
    Zacks14 days ago

    Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

    The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

  • Ionis Pharmaceuticals’ Revenue Growth Rate
    Market Realist14 days ago

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.

  • 5 Best Biotech Stocks to Buy In October
    Zacks16 days ago

    5 Best Biotech Stocks to Buy In October

    Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

  • A Financial Overview of Alexion Pharmaceuticals
    Market Realist19 days ago

    A Financial Overview of Alexion Pharmaceuticals

    In the first half this year, Alexion Pharmaceuticals’ (ALXN) revenue grew 11% YoY (year-over-year) to $1.98 billion from $1.78 billion. Alexion’s Soliris generated revenue of $1.7 billion in H1 2018, with revenue of $800.1 million and $898.2 million in the first and second quarters, respectively.

  • Alexion Pharmaceuticals to Acquire Syntimmune
    Market Realist19 days ago

    Alexion Pharmaceuticals to Acquire Syntimmune

    On September 26, Alexion Pharmaceuticals (ALXN) entered into an agreement with Syntimmune, wherein Alexion will acquire Syntimmune with an upfront payment of $400.0 million. Syntimmune is also eligible for milestone payments of up to $800 million, bringing the total value of the transaction to $1.2 billion.

  • Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion
    Zacks20 days ago

    Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion

    Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.

  • Company News For Sep 27, 2018
    Zacks20 days ago

    Company News For Sep 27, 2018

    Companies in the news are: WOR, ALXN, NKE and PZZA

  • ACCESSWIRE20 days ago

    Today’s Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 27, 2018 / Separate positive developments sent shares of biotech stocks Aldeyra Therapeutics and Alexion Pharmaceuticals higher on Wednesday. It was encouraging phase 2b trial results from Aldeyra and acquisition news from Alexion Pharmaceuticals that had traders cheering. Aldeyra Therapeutics, Inc. shares were up nearly 35% at the close yesterday on colossal trading volume compared to usual.

  • Barrons.com21 days ago

    The Dow Can’t Handle the Fed’s Truth

    The Dow initially added to its gains after the Federal Reserve raised rates but the good mood didn’t survive Fed Chief’s Jerome Powell’s press conference. …and explain why Alexion Pharmaceuticals soared to the top of the S&P 500. Stocks tried to break a two-day losing streak Wednesday but sank in the last hour of trading, following the Fed’s press conference.

  • Investor's Business Daily21 days ago

    Here's Why The Stock Market Sold Off After The Fed Meeting

    Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.